HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
0.794
+0.042 (5.63%)
At close: May 31, 2024, 4:00 PM
0.810
+0.016 (2.00%)
After-hours: May 31, 2024, 7:54 PM EDT
HOOKIPA Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for HOOKIPA Pharma stock have an average target of 4.06, with a low estimate of 2.25 and a high estimate of 5.00. The average target predicts an increase of 411.34% from the current stock price of 0.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HOOKIPA Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +529.72% | May 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6.5 → $5 | Strong Buy | Maintains | $6.5 → $5 | +529.72% | Apr 26, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +529.72% | Mar 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +718.64% | Mar 25, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +529.72% | Jan 30, 2024 |
Financial Forecast
Revenue This Year
56.58M
from 20.13M
Increased by 181.07%
Revenue Next Year
18.82M
from 56.58M
Decreased by -66.74%
EPS This Year
-0.26
from -0.86
EPS Next Year
-0.62
from -0.26
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 76.2M | 26.3M | 15.8M | 104.9M | 289.5M |
| Avg | 56.6M | 18.8M | 8.9M | 61.5M | 191.5M |
| Low | 41.7M | 11.7M | 2.5M | 20.2M | 97.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 278.7% | -53.6% | -16.3% | 1,075.7% | 371.1% |
| Avg | 181.1% | -66.7% | -52.6% | 588.7% | 211.6% |
| Low | 107.4% | -79.4% | -87.0% | 126.0% | 59.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.16 | -0.51 | -0.80 | -0.44 | 0.20 |
| Avg | -0.26 | -0.62 | -0.84 | -0.53 | 0.08 |
| Low | -0.30 | -0.66 | -0.87 | -0.61 | -0.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.